Related by context. All words. (Click for frequent words.) 75 registrational trial 75 phase IIb clinical 74 phase IIa clinical 72 Phase Ib 72 Phase IIIb clinical 72 SUCCEED trial 72 phase IIb trial 72 obatoclax 71 MAA submission 71 Zenvia ™ 71 confirmatory Phase III 71 alvespimycin 71 pivotal Phase III 71 IMA# 71 oral ridaforolimus 71 phase IIb 71 Phase IIb clinical 70 phase IIa 70 Phase III clinical 70 ofatumumab 70 deforolimus 70 FOLOTYN ® 70 Phase Ib clinical 70 Phase #/#a 70 Phase 2a trial 70 Phase Ib II 70 phase Ib 70 Phase Ib study 70 BLA submission 70 lintuzumab 70 Phase IIa trial 70 BLA filing 70 Phase 2b trial 70 Phase 1b trial 69 rALLy clinical trial 69 elotuzumab 69 Phase #b/#a 69 Phase IIb trials 69 tanespimycin 69 Phase 1b 69 Phase 2b study 69 OMAPRO 69 Phase 2b clinical 69 multicenter Phase II 68 CR# vcMMAE 68 BRIM3 68 Phase IIa trials 68 Biologics License Application BLA 68 AP# [003] 68 Azedra 68 Phase III 68 forodesine 68 Phase IIb clinical trials 68 torezolid phosphate 68 OvaRex ® MAb 68 registrational trials 68 Marqibo 68 lorvotuzumab mertansine 68 Phenoptin 68 Alzhemed TM 68 IND submission 68 dose escalation Phase 68 Phase III clinical trials 68 ganetespib 68 IIa trial 67 Phase IIa clinical 67 Phase 1b clinical 67 PREOS 67 SNT MC# 67 Urocidin 67 ELACYT 67 Phase IIb 67 Phase IIb trial 67 axitinib 67 sunitinib malate 67 dirucotide 67 dose escalation clinical 67 Zerenex 67 multicenter Phase 67 ridaforolimus 67 INCB# [001] 67 PANVAC VF 67 IMC #B 67 Phase III TRIST 67 teduglutide 67 ponatinib 67 EndoTAG TM -1 67 Virulizin R 67 Cloretazine ® 67 TACI Ig 67 StemEx R 67 clinical pharmacology studies 67 Troxatyl 67 phase IIb study 67 NDA submission 67 JAK inhibitor 67 rALLy trial 67 Phase IIb III 67 Phase 2b clinical trials 67 Phase #b/#a clinical 67 Phase 2a 67 PEG SN# 67 CRMD# 67 Topical Interferon Alpha 2b 67 Phase III pivotal 67 Phase 1a clinical 67 otelixizumab 67 pivotal bioequivalence 67 CoFactor 67 placebo controlled Phase 67 randomized controlled Phase 67 Surfaxin LS 67 PDE4 inhibitor 67 Allovectin 7 67 HCV protease inhibitor 67 MAGE A3 ASCI 66 vosaroxin 66 enzastaurin 66 Phase III trials 66 L BLP# 66 talactoferrin 66 BAY #-# 66 Dacogen injection 66 MGCD# [001] 66 RIGScan CR 66 Aurexis 66 GALNS 66 oral deforolimus 66 Trofex 66 Phase 2b 66 placebo controlled Phase III 66 Amigal 66 sNDA submission 66 Phase #/#a trial 66 investigational therapies 66 ILLUMINATE 66 Traficet EN 66 Bicifadine 66 ATL# [001] 66 Amrubicin 66 HuMax CD4 66 confirmatory Phase 3 66 PXD# 66 PIX# trial 66 pivotal Phase 66 MOZOBIL 66 Personalized Immunotherapy 66 ularitide 66 Archexin 66 Rhucin R 66 severe hypercholesterolemia 66 Phase IIB 66 Phase 2a clinical 66 Zenvia Phase III 66 relapsed refractory multiple myeloma 66 ONCONASE R 66 HCD# [002] 66 pharmacokinetic PK 66 clofarabine 66 phase 2a 66 Evoltra ® 66 OvaRex R 66 Tarvacin TM 66 lumiliximab 66 investigational humanized monoclonal antibody 65 bardoxolone 65 lintuzumab SGN 65 Asentar 65 Glybera 65 randomized Phase 65 HGS ETR1 65 elacytarabine 65 GED aPC 65 eniluracil 65 Aryplase 65 Aplidin 65 Phase III randomized controlled 65 Phase III confirmatory 65 belinostat 65 PRECISE trial 65 GLP toxicology studies 65 ALN TTR 65 zanolimumab 65 Viramidine 65 ofatumumab HuMax CD# 65 HGS# 65 HER2 positive metastatic breast 65 Ceflatonin 65 tamibarotene 65 Genz # 65 ONCONASE 65 hoFH 65 Plicera 65 PREOS R 65 vidofludimus 65 maribavir 65 randomized Phase IIb 65 KNS # 65 FOLOTYN 65 dextromethorphan quinidine 65 vascular disrupting agent 65 Phase IIIb 65 TOCOSOL Paclitaxel 65 riociguat 65 APEX PD 65 Firazyr 65 AIM HIGH 65 NO# [002] 65 celgosivir 65 tezampanel NGX# 65 alvimopan 65 ENRICH trial 65 glufosfamide 65 Bezielle 65 LUX Lung 65 pralatrexate 65 romidepsin 65 Marketing Authorization Application 65 dose escalation trial 65 HuMax EGFr 65 Phase #b/#a trial 65 Insegia 65 Glybera R 65 phase Ib clinical 65 Phase IIa 65 Actimmune ® 65 ALN TTR# 65 IMGN# 65 tesmilifene 64 CEQ# 64 sapacitabine 64 ALN PCS 64 Viprinex TM 64 Prostate AdenoCarcinoma Treatment 64 EOquin 64 subcutaneous formulation 64 RSD# oral 64 mitogen activated ERK kinase 64 NP2 Enkephalin 64 SAR# [004] 64 neratinib 64 ruxolitinib 64 TRISENOX 64 Bronchitol 64 thymalfasin 64 YONDELIS 64 palifosfamide 64 Shigamabs ® 64 Icatibant 64 BrachySil TM 64 PSN# [002] 64 Fibrillex TM 64 Augment Injectable 64 omacetaxine mepesuccinate 64 Phase IIa clinical trials 64 LymphoStat B 64 tezampanel 64 ixabepilone 64 Quinamed 64 PNP inhibitor 64 valopicitabine 64 metastatic hormone refractory 64 anticancer compound 64 Allovectin 7 ® 64 INCB# [002] 64 blinatumomab 64 docetaxel Taxotere R 64 Mipomersen 64 HGS ETR2 64 AQ4N 64 Tanespimycin 64 MEND CABG II 64 XmAb# 64 pomalidomide 64 Panzem R NCD 64 Plenaxis TM 64 abiraterone acetate 64 Biologics License Application 64 investigational hepatitis C 64 Vectibix panitumumab 64 HuLuc# 64 TOLAMBA 64 Clavis Pharma 64 Phase III HEAT 64 Veronate 64 Phase Ib clinical trials 64 PLK1 SNALP 64 mipomersen 64 Tarceva TM 64 IL# PE#QQR 64 Cethrin 64 EOquin TM 64 PRTX 64 Phase 2a clinical trials 64 Pirfenidone 64 Fodosine 64 JAK2 inhibitor 64 tiapamil 64 PROMACTA 64 Genasense ® 64 dose cohort 64 PDX pralatrexate 64 investigational compound 64 EFAPROXYN 64 midstage studies 64 mertansine 64 Evoltra TM 64 PROVENGE sipuleucel T 64 Allovectin 7 R 64 LUMINATE 64 Telatinib 64 Vilazodone 64 PRIMO CABG 64 Onalta ™ 64 Cloretazine R VNP#M 64 TELINTRA 64 Zelrix 64 Cladribine Tablets 64 OncoGel 64 leading oral taxane 64 Ophena TM 64 DPX Survivac 64 fund BioSante LibiGel 64 Loramyc R 64 EchoCRT 63 Corlux 63 initiate Phase IIb 63 AVADO 63 varespladib 63 initiate Phase 1b 63 lomitapide 63 cardio renal 63 Evoltra 63 AEG# 63 Tyrima 63 virus HCV protease inhibitor 63 histone deacetylase HDAC inhibitor 63 APPRAISE 63 ongoing Phase 1b 63 BRIM2 63 Oracea TM 63 PRECISE Trial 63 Stimuvax R 63 acyclovir Lauriad R 63 NEBIDO 63 PROPEL trial 63 oral methylnaltrexone 63 seliciclib CYC# 63 Nuvion 63 huC# DM4 63 brentuximab vedotin 63 FavId 63 inhaled liposomal ciprofloxacin 63 PRT# 63 pradefovir 63 PrevOnco ™ 63 incyclinide 63 Soliris TM eculizumab 63 TELCYTA 63 Virulizin ® 63 Troxatyl TM 63 EDEMA3 63 cystinosis patients 63 metastatic sarcomas 63 MEK inhibitor 63 octreotide implant 63 blinded randomized placebo controlled 63 Panzem R 63 Phase 1a 63 ATryn R 63 Phase IIB clinical 63 dose cohorts 63 ZYBRESTAT 63 synthetic retinoid 63 PrevOnco 63 APEX AMI trial 63 TMC# [002] 63 Phase 2b kidney transplant 63 novel histone deacetylase 63 StemEx 63 UPLYSO 63 Sulonex TM 63 ongoing Phase IIIb 63 AeroLEF TM 63 Exherin TM 63 MERLIN TIMI 63 cannabinor 63 R#/MEM # 63 SYMMETRY trial 63 ISTODAX 63 Phase Ib IIa 63 eprotirome 63 TBC# 63 CINTREDEKIN BESUDOTOX 63 picoplatin 63 Elagolix 63 Phase IIIb study 63 cabozantinib 63 PFO migraine 63 ZADAXIN ® 63 NUVIGIL 63 viral kinetic 63 pertuzumab 63 voreloxin 63 VEGF Trap 63 refractory metastatic colorectal cancer 63 eltrombopag 63 Tracleer r 63 ANCHOR trial 63 omacetaxine 63 MT#/MEDI-# 63 antibody MAb 63 adecatumumab MT# 63 GAMMAGARD 63 HepeX B 63 SUTENT ® 63 Orathecin 63 ospemifene 63 vemurafenib 63 placebo controlled clinical 63 oral taxane 63 PHX# 63 rNAPc2 63 Trizytek 63 Zavesca r 63 midstage trials 63 reslizumab 63 Pralatrexate 63 refractory chronic lymphocytic 63 entinostat 63 oral prodrug 63 brentuximab vedotin SGN 63 Huntexil 63 IND CTA 63 farletuzumab 63 MBP# [001] 63 OncoVEX GM CSF 63 Onconase 63 randomized Phase III 63 PRX # 63 Dalbavancin 63 BEXXAR 63 ZYBRESTAT TM 63 evaluating REVLIMID 63 Zybrestat 63 tesetaxel 63 multicenter Phase III 63 Hedgehog antagonist 63 Cimzia TM 63 Cloretazine R 63 Diamyd ® 63 relapsed MCL 63 REVIVE Diabetes 63 HspE7 63 bicifadine 63 orphan designation 63 cetrorelix 63 trastuzumab DM1 T DM1 63 BCX# 63 confirmatory clinical 63 GATTEX ® 62 Phase III psoriasis 62 Octreolin 62 Stedivaze 62 Ereska 62 Solazed 62 CLARITY study 62 OHR/AVR# 62 generation purine nucleoside 62 MEK inhibitor RDEA# 62 Onrigin 62 UVIDEM 62 compound INCB# 62 tramiprosate ALZHEMED TM 62 relapsed multiple myeloma 62 Chemophase 62 oral salmon calcitonin 62 ADVANCE PD 62 MAXY alpha 62 fostamatinib 62 Azedra ™ 62 refractory Hodgkin lymphoma 62 novel oral anticoagulant 62 unblinding 62 Restanza 62 Fast Track designation 62 Annamycin 62 KIACTA ™ 62 DCCR 62 tramiprosate Alzhemed TM 62 Solazed TM 62 Clolar 62 Clolar ® 62 ASONEP 62 atacicept 62 SEPET TM 62 LEP ETU 62 RhuDex ® 62 ATryn ® 62 dacetuzumab 62 Intravenous CP 62 Teysuno 62 IRESSA 62 T DM1 62 BioNumerik 62 Biologic License Application BLA 62 custirsen 62 liprotamase 62 COMFORT II 62 clinical trial 62 nab paclitaxel 62 velafermin 62 LibiGel ® 62 trastuzumab emtansine T DM1 62 ZYBRESTAT fosbretabulin 62 Raptiva R 62 phase IIIb 62 SCH # 62 PROSTVAC TM 62 Clonicel 62 PSMA ADC 62 Ventavis 62 glucokinase activator 62 Phase lll 62 IMPACT IMmunotherapy 62 dosing cohort 62 OncoVEX 62 MIST II 62 IND Investigational New 62 clinicaltrials 62 TLK# 62 TroVax 62 nalbuphine ER 62 ritonavir boosted danoprevir 62 Exelixis XL# 62 Phase 1b dose escalation 62 ZOLINZA 62 ANTEGREN 62 Neuradiab 62 Omigard 62 budesonide foam 62 MAXY G# 62 Carfilzomib 62 velafermin belinostat 62 Amplimexon 62 Civacir 62 Raptiva ® 62 assessing T DM1 62 AZILECT ® 62 ITAX 62 rindopepimut 62 AVN# [001] 62 lymphoma CTCL 62 NGX# 62 CIMZIA TM 62 perifosine 62 MKC# MT 62 ASA# 62 Plenaxis R 62 AzaSite Plus 62 opioid induced bowel dysfunction 62 vilazodone 62 Nanobody 62 daclizumab 62 CCX# 62 ThermoDox ® 62 Lymphoseek ® 62 IND enabling 62 Targretin 62 lorcaserin Phase 62 darapladib 62 refractory CLL 62 Rebif ® 62 Orazol 62 tolerated dose MTD 62 Nexavar ® 62 fosbretabulin 62 ThermoDox ® clinical 62 Reolysin 62 pharmacokinetic PK study 62 BiTE R 62 investigational pan BCR 62 refractory APL 62 Pivotal Phase III 62 registrational studies 62 Voraxaze 62 DR Cysteamine 62 Harry Palmin President 62 ACOMPLIA R 62 THALOMID 62 histamine dihydrochloride 62 LEUKINE 62 dose escalation 62 receptor tyrosine kinase inhibitor 62 MEND CABG 62 Myocet 62 IMC A# 62 oral calcitonin 62 sorafenib tablets 62 NEUVENGE 62 #D#C# 62 ataluren 62 dirucotide MBP# 62 COSIRA trial 62 velaglucerase alfa 62 atrasentan 62 CINQUIL 62 Æterna Zentaris 62 oral FTY# 62 Urocidin TM 62 Rhucin ® 62 heavily pretreated 62 crizotinib PF # 62 eculizumab 62 Serdaxin 62 Zerenex ™ 62 AZILECT R 62 TASKi2 62 mGluR5 negative 62 IIb clinical trial 62 pharmacodynamic PD 62 Triolex 62 Feraheme 62 liposomal formulation 62 Theratope 62 ocrelizumab 62 hypoxia activated prodrug 62 BCIRG 62 mRCC 62 randomized Phase 2b 62 denufosol 61 Phase II 61 NPSP# 61 metaglidasen 61 Phase III multicenter 61 BiTE 61 TRO# 61 PROPEL 61 Ambrisentan 61 REOLYSIN ® 61 Cetrorelix 61 PEG PAL 61 Apoptone 61 DermaVir Patch 61 STRIDE PD 61 ezogabine 61 BiTE antibody 61 Androxal 61 Phase III Pivotal 61 ascending dose 61 MONOVISC 61 amrubicin 61 L MTP PE 61 refractory multiple myeloma 61 JZP 61 USL# 61 AIMM trial 61 HoFH 61 GSK# [001] 61 Zemplar Capsules 61 methylnaltrexone 61 Fx #A 61 Manja Bouman CEO 61 NDA resubmission 61 Androxal TM 61 Prestara 61 MoxDuo IR 61 MyVax R 61 OXi# 61 ALN VSP Phase 61 TKM ApoB 61 RE LY 61 CCR9 antagonist 61 bendamustine 61 Marketing Authorization Application MAA 61 recurrent NSCLC 61 evaluating satraplatin 61 BST CarGel R 61 Golimumab 61 CLL8 61 Somatuline R Autogel R 61 RELOVAIR ™ 61 rilonacept 61 Abiraterone acetate 61 budesonide MMX Phase III 61 QLT# 61 TYZEKA 61 tivozanib 61 Capesaris 61 TMC# C# 61 KRN# 61 Zenvia TM 61 DDP# 61 controlled multicenter 61 Phase Ia 61 ZACTIMA 61 nonclinical studies 61 EDEMA4 61 multicentre randomized 61 Diabetic Macular Edema 61 LungExpress Dx TM 61 MGd 61 carfilzomib 61 REBETOL combination therapy 61 RG# [001] 61 Phase 1b clinical trials 61 Orphan Drug status 61 CA4P 61 adecatumumab 61 BLOOM DM 61 LUVENIQ 61 vernakalant oral 61 Viprinex 61 MabCampath 61 Urocortin 2 61 optimal dosing 61 Onco TCS 61 indolent NHL 61 orally bioavailable 61 Junovan 61 bazedoxifene 61 Ophena 61 investigational monoclonal antibody 61 GetGoal Phase III 61 ALN VSP 61 rFVIIIFc 61 brivaracetam 61 CLIRS trial 61 omega interferon 61 rALLy 61 AVASTIN 61 ARIKACE 61 BR.# 61 peginesatide 61 balsalazide tablet 61 castrate resistant prostate cancer 61 systemic anaplastic large 61 Tracleer R 61 Nexavar sorafenib 61 VitiGam 61 ZEVALIN ® 61 IRX 2 61 trastuzumab DM1 61 cangrelor 61 CHAMPION PCI 61 DAVANAT R 61 BrachySil 61 catheter occlusion 61 GAP #B# 61 ACCLAIM II 61 6R BH4 61 Ceflatonin R 61 PI3K/Akt pathway inhibitor 61 epigenetic therapies 61 HRPC 61 vinflunine 61 ALN RSV# 61 Altastaph 61 Rhucin 61 Saforis 61 sNDA 61 dimebon 61 AA amyloidosis 61 EGS# 61 BEMA TM Fentanyl 61 regorafenib 61 ARIKACE ™ 61 ThermoDox R 61 hormone refractory prostate cancer 61 Anturol TM 61 lymphoid malignancies 61 LibiGel Phase III 61 Azixa 61 volociximab 61 GATTEX 61 PREGNANT Study 61 Azilect ® 61 investigational antiplatelet agent 61 Blinatumomab 61 orBec 61 Xanafide 61 Prodarsan ® 61 LE DT 61 follicular non 61 CIP TRAMADOL ER 61 non nucleoside HCV 61 Benlysta belimumab 61 NV1FGF 61 Hexvix 61 pseudobulbar affect PBA 61 including eniluracil ADH 61 TG# [001] 61 Perifosine 61 GFT# 61 OMAPRO ™ 61 refractory AML 61 PROVENGE ® 61 BRILINTA 61 Pivotal Trial 61 WILEX 61 interferon gamma 1b 61 LHRH antagonist 61 ApoB SNALP 61 SILENOR 61 Fentanyl TAIFUN R 61 multicenter clinical 61 Mozobil 61 StaphVAX 61 cutaneous T cell 61 zileuton CR 60 dose escalation study 60 OMNARIS Nasal Spray 60 FRDA 60 satraplatin 60 ELADUR 60 Vicinium TM 60 MORAb 60 ProLindac 60 NVA# 60 aclidinium bromide 60 rhC1INH 60 Celacade TM 60 VALOR trial 60 TREANDA 60 epothilone 60 Nasdaq OPTR 60 Ganite ® 60 RIGScan 60 VITAL Trial 60 Neo Urinary Conduit 60 Alocrest 60 APTIVUS 60 Betaferon ® 60 Optiquel ™ 60 pharmacodynamic effects 60 JAK1 60 pegloticase 60 Lucanix R 60 Poly ICLC 60 ROTATEQ 60 dose escalation phase 60 visilizumab 60 Proxinium TM 60 Mr. Bentsur 60 isoform selective 60 lucinactant 60 TRANSDUR Sufentanil 60 XL# XL# XL# 60 APTIMA HPV assay 60 Firazyr ® 60 IIa clinical 60 initiate Phase 2b 60 Lenocta 60 QNEXA 60 targeted radiotherapeutic 60 ZEGERID Capsules 60 tafamidis 60 Acapodene 60 Cloretazine 60 Hematide ™ 60 Taxotere ® 60 PEGylated interferon beta 1a 60 epratuzumab 60 Entereg R 60 diarrhea predominant irritable 60 XL# [003] 60 Pruvel 60 SYCREST 60 metastatic HRPC 60 imetelstat 60 forodesine hydrochloride 60 Neurodex TM 60 denosumab oncology 60 eprodisate KIACTA TM 60 CYT# potent vascular disrupting 60 evaluating tivozanib 60 Alpharadin 60 diabetic neuropathic pain 60 AMITIZA R 60 Cimzia ® certolizumab pegol 60 Aflibercept 60 novel VDA molecule 60 refractory acute myeloid 60 afatinib 60 Prodarsan 60 APEX AMI 60 midstage clinical 60 RGB # 60 Vernakalant 60 pediatric Crohn disease 60 immatics 60 Xcellerated T Cells 60 lesinurad 60 Phase III Clinical Trial 60 selective androgen receptor modulator 60 Xcytrin R 60 Xyrem ® 60 MDV# 60 metastatic CRC 60 BioSTAR R 60 PCK# 60 Evoltra R 60 Exelixis compounds 60 crofelemer 60 CA9 SCAN 60 superficial bladder cancer 60 lubiprostone 60 Somatuline Depot 60 oncolytic virus therapies 60 EndoTAG TM 60 RNAi therapeutic targeting 60 MIRCERA 60 pain palliation 60 Panzem 60 oritavancin 60 GRAVITAS trial 60 ONCASPAR 60 LymphoStat B TM 60 APOPTONE 60 Dapagliflozin 60 VNP#M 60 Ruconest 60 SonoLysis 60 NOX E# 60 GLPG# 60 orphan medicinal product 60 relapsed MM 60 systemic ALCL 60 CCX# B 60 SCIB1 60 ICA # 60 FIRMAGON R 60 paclitaxel poliglumex 60 multi kinase inhibitor 60 dalbavancin 60 Tocosol Paclitaxel 60 RoACTEMRA 60 generation HCV protease 60 immunotherapeutic vaccine 60 ADVEXIN 60 teriflunomide 60 biologic therapy 60 Xerecept 60 IIa trials 60 Mepact 60 ProSavin 60 MGCD# clinical trials 60 URG# 60 Maximum Tolerated Dose 60 supplemental Biologics License Application 60 Tavocept 60 relapsed refractory 60 Vitaxin 60 ATTRACT 60 DXL# 60 APD# 60 AMD# [002] 60 viral kinetics 60 Ocrelizumab 60 oxymorphone ER 60 Omapro 60 GATTEX TM 60 CUSTOM III 60 elagolix 60 orally administered inhibitor 60 eritoran 60 TroVax ® 60 SinuNase ™ 60 sBLA 60 ThGRF 60 tolevamer 60 HCV SPRINT 60 Alnylam #x# 60 ROCKET AF 60 investigational drug 60 tranilast 60 phase IIb III 60 MyVax personalized immunotherapy 60 FDA Investigational Device 60 AMR# 60 Hematide ™ peginesatide 60 NEUMUNE 60 INDs 60 Nanobody ® 60 Alvesco R 60 apaziquone 60 IPX# 60 PF # [002] 60 CytoFab 60 sitaxsentan 60 PEARL SC 60 Liprostin 60 pharmacokinetic studies 60 humanized monoclonal antibody 60 evaluating Actimmune 60 ISIS # 60 DASISION 60 Atiprimod 60 multicenter randomized placebo controlled